Biogen’s tau-lowering drug slows cognitive decline in early study of Alzheimer’s disease

An experimental treatment for Alzheimer’s disease that removes a toxic protein called tau from brain cells showed “favorable trends” across several measures of cognition and function in a small study — results that offer some hope for an emerging drug class that has failed to deliver benefits in the past.

The drug, called BIIB080, is being developed by Biogen.

“We are very encouraged by the consistency of the data,” said Priya Singhal, Biogen’s chief of drug development, while also emphasizing the company is not trying to oversell the significance of the findings. “These are exploratory outcomes from a very small study,” she added.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In